Groundbreaking Presentation at The Aesthetic MEET 2025
At The Aesthetic MEET 2025 conference, renowned plastic surgeon Prof. Anand Deva presented remarkable new clinical findings from BellaSeno regarding their innovative breast implants. This presentation highlighted the impressive outcomes of their 3D-printed, resorbable scaffolds, which signal a major advancement in aesthetic surgery.
Significant Clinical Findings
The study involved a clinical trial that commenced in 2022, with 19 patients receiving BellaSeno's advanced, polycaprolactone-based breast scaffolds after their silicone implants were removed. Follow-up assessments revealed an outstanding 87% retention of breast volume after one year, accompanied by low complication rates and marked improvements in both physical and psychological well-being.
Enhanced Patient Outcomes
Patients reported increased quality of life, complimenting the natural softness and shape of the scaffolds. Notably, no common problems typically associated with silicone implants or fat grafting, such as capsular contractures, infections, or necrosis, were documented. For participants who reached the two-year follow-up, Prof. Deva's team observed effective vascularization and the development of a vascular network in the newly reconstructed breast tissue.
Safe Alternatives for Patients
In light of these findings, Prof. Deva asserted that BellaSeno has uncovered a safe and high-performing alternative to traditional silicone implants. He emphasized the significant advantage of these implants in promoting the body's natural regenerative potential, allowing for the replacement of tissue in a way that aligns with the body's own healing capabilities.
Comments from Company Leadership
Mohit Chhaya, the CEO of BellaSeno, expressed his satisfaction with the study's results. He remarked, “This represents a key milestone that showcases our revolutionary approach as a risk-optimized, high-quality alternative for patients affected by silicone implant complications. Our scaffold technology not only preserves breast shape and volume but also ensures a desirable softness—a crucial factor for patient satisfaction.”
About BellaSeno
BellaSeno GmbH, founded in 2015, operates from its headquarters in Leipzig, Germany, and maintains a subsidiary in Brisbane, Australia. The company specializes in developing resorbable soft tissue and bone reconstruction implants, utilizing advanced additive manufacturing techniques under ISO 13485 certification. BellaSeno has garnered substantial support from private investors and various governmental institutions, which underscores the growing trust in its innovative technology.
Commitment to Innovation
Through ongoing efforts and investment, BellaSeno continues to push the boundaries of traditional implant technologies. The company's focus on scientific research aims to enhance clinical practices and improve overall patient outcomes, providing safer and more effective solutions in aesthetic medicine.
Contact Information
For further inquiries, BellaSeno can be reached via the following contact details:
BellaSeno GmbH
Dr. Mohit Chhaya
Email: mohit.chhaya@bellaseno.com
Phone: +49 176 2283 9583
Frequently Asked Questions
What are BellaSeno’s breast scaffolds made from?
BellaSeno's breast scaffolds are made from a polycaprolactone-based material, designed to be resorbable.
What were the findings from the clinical trial?
The clinical trial showed an 87% volume retention, low complication rates, and successful vascularization over time.
Who presented the data at the conference?
The clinical data on BellaSeno's breast implants were presented by Prof. Anand Deva.
How does BellaSeno's technology differ from traditional implants?
BellaSeno's technology focuses on resorbable materials that align with the body’s natural regeneration, unlike traditional silicone implants.
Where is BellaSeno headquartered?
BellaSeno GmbH is headquartered in Leipzig, Germany, with additional operations in Brisbane, Australia.
